Description of the medicine: Decylate (Decilatum)
Sodium 2-methyl-7-ethylundecyl-4-sulfate solution.
Synonyms: Trombovar, Obliterol, Sotradecol, Tergitol-4, Trombovar, Varicol, etc.
Available in 1% and 3% solution (in phosphate buffer) in 2 ml ampoules. Transparent colorless liquid.
Decylate is a venosclerosing drug with surface-active properties. A solution of decylate, when introduced into the veins, causes thrombus formation with the subsequent organization of a blood clot and its fusion with the vessel wall.
It is used for conservative injection-sclerosing treatment of varicose veins of the lower extremities. The drug is used in the treatment of patients with initial and uncomplicated forms of moderately severe varicose veins of the superficial veins, as well as in the disseminated type of varicose veins, when the surgical removal of all varicose veins is practically impossible. In complex therapy, decylate is used in combination with surgical treatment, as well as in the postoperative period for sclerotherapy of “disconnected” varicose inflows of saphenous veins.
Decilate treatment is carried out only with absolute confidence in the good patency of the deep and communicative veins of the lower extremities. Before conducting a course of venosclerosing therapy, it is necessary to make a test introduction of decylate to identify possible individual intolerance. Before the introduction of the drug, with the patient standing, one of the most pronounced distally located varicose nodes is chosen, into which a needle is inserted perpendicular to the skin surface (without a syringe). As soon as blood begins to flow from the needle, the patient is laid on his back, and his leg is raised at an angle of 30 - 40 '. After the introduction of decylate, the puncture site is pressed with a sterile gauze ball, and the needle is removed. The puncture site is closed with a bandage, the leg remaining in an elevated position, bandaged with an elastic bandage from the toes to the upper third of the thigh. To prevent possible damaging effects of decylate on the deep vein endothelium with their subsequent thrombosis, patients should immediately walk for at least 2 to 3 hours immediately after injection of the drug.
If it is necessary to conduct a phased injection-sclerosing treatment, sclerosis of superficial veins begins from the lateral branches, and decylate is introduced last in the main venous trunk.
With moderate varicose veins and the presence of soft, easily decaying nodes, a 1% decylate solution is used, and in the presence of large nodes with thickened dense walls, a 3% solution of the drug is used. For one treatment session, the drug is administered in 2 to 6 points, 0.5 to 2 ml each.
In the presence of an extensive widespread varicose process, injections of the decylate solution are repeated 2-10 times at intervals of 3-5 days. The maximum amount of the drug per treatment course is 6 - 30 ml of 1% solution and 4 - 10 ml of 3% solution.